Insight

A trial of radiolabeled antibody yttrium-90–FF-21101 for the treatment of advanced ovarian and other cancers

Devalingam Mahalingam/cancer.northwestern.edu

Jan 12, 2025, 19:24

A trial of radiolabeled antibody yttrium-90–FF-21101 for the treatment of advanced ovarian and other cancers

A recent paper by Devalingam Mahalingam, Professor of Medicine at Northwestern University Feinberg School of Medicine, was mentioned by ACS Journal Cancer on X:

“Open Access and available now.

This clinical trial of a P-cadherin-directed therapy proved unsuccessful, but valuable lessons are learned. Further investigation may yet achieve the therapeutic potential of targeting P-cadherin.

Read the study.”

“A trial of radiolabeled antibody yttrium-90–FF-21101 for the treatment of advanced ovarian and other cancers”

Authors: Devalingam Mahalingam, Taofeek Owonikoko, Ebrahim Delpassand, Catherine Wheeler, Debra Richardson et al.

A trial of radiolabeled antibody yttrium-90–FF-21101 for the treatment of advanced ovarian and other cancers :

More posts featuring ACS Journal Cancer.

ACS Journal Cancer cancer Catherine Wheeler Debra Richardson Devalingam Mahalingam Ebrahim Delpassand OncoDaily Oncology Ovarian Cancer P-cadherin Taofeek Owonikoko

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Speakers of the 2025 CACA-OncoDaily-SPCC Cancer Summit: Bridging Continents

Alcohol and Cancer Risk: The U.S. Surgeon General’s Advisory 2025

Special Coverage